Song, S., Ha, S., Park, J., Park, S., Shin, S. H., Oak, C., . . . Yoo, H. (2020). A randomized, multi-center, open-label study to compare the safety and efficacy between afatinib monotherapy and combination therapy of afatinib and HAD-B1 for the locally advanced or metastatic NSCLC patients with EGFR mutations. Medicine (Baltimore).
Styl ChicagoSong, Si-Yeon, et al. "A Randomized, Multi-center, Open-label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy of Afatinib and HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations." Medicine (Baltimore) 2020.
Citace podle MLASong, Si-Yeon, et al. "A Randomized, Multi-center, Open-label Study to Compare the Safety and Efficacy between Afatinib Monotherapy and Combination Therapy of Afatinib and HAD-B1 for the Locally Advanced or Metastatic NSCLC Patients With EGFR Mutations." Medicine (Baltimore) 2020.